CompletedPhase 4

Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

United States70 participantsStarted 2023-11-06

Plain-language summary

The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant recipients who are at risk for this type of infection, while also assessing the tolerability of these two regimens. The two medication regimens being compared are Valganciclovir (FDA approved to prevent and treat CMV infection) vs Maribavir (FDA approved to treat CMV infection) plus Acyclovir (FDA approved to prevent HSV infection).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Kidney transplant recipient at study institution * =7 days of transplant * Received at least one dose of rATG induction or patient is D+/R- CMV serostatus Exclusion Criteria: * Age \<18 years at time of transplant * Recipient of pancreas, liver, heart, lung transplant * Recipient of investigational, non-FDA approved medication

What they're measuring

Clinical Significant Leukopenia

Timeframe: One year following transplant

CMV Infection

Timeframe: One year following transplant

Trial details

NCT IDNCT06034925

SponsorMedical University of South Carolina

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-30

Results submitted2026-03-27

View on ClinicalTrials.gov More Transplant Complication trials